anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To improve or enhance the antibacterial effect of a collyrium compsn. by adding a specified anionic surfactant such as a sarcosinate to the collyrium compsn. contg. a cationic antibacterial agent, a polyelectrolyte and an active component. CONSTITUTION: An anionic surfactant such as a sarcosinate represented by formula I [where R&lt;1&gt; is a 4-27C hydrocarbon, M is H or a pharmaceutically allowable salt and (n) is 1, 2 or 3], e.g. lauroyl sarcosine or lactylate represented by formula II (where R&lt;2&gt; is a 4-27C hydrocarbon), e.g. sodium capryl lactylate is added to a collyrium compsn. contg. a cationic antibacterial agent such as benzalkonium chloride, a polyelectrolyte such as a carboxyvinyl polymer and an active component such as betaxolol hydrochloride by such an amt. as to enhance the antibacterial effect of the collyrium compsn. The bonding of the antibacterial component of the collyrium compsn. to other component is prevented or suppressed and the antibacterial effect of the collyrium compsn. is improved or enhanced.
PURPOSE:To prevent deterioration in activity of lymphotoxin and remarkably improve stability, by adding albumin, globulin or gelatin to the lymphotoxin. CONSTITUTION:Albumin, e.g. human blood serum albumin, globulin, e.g. human gamma-globulin, and gelatin alone or in combination or two or more thereof are added to powder of lymphotoxin having antitumor activity or a solution prepared by dissolving the lymphotoxin in an aqueous medium, e.g. water or buffer solution, etc., in a production or formulation process of the lymphotoxin. The above-mentioned albumin, etc., are added in a amount to give &gt;=1ppm, preferably &gt;=1,000ppm concentration in the solution of the lymphotoxin.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a UV light-preventive cosmetic material having sufficient water resistance and easily washed out by presenting a UV light-preventive cosmetic material without blending a surfactant and an oil-based component incompatible with soaps such as a high viscosity silicone oil, and a method for producing the same.  &lt;P&gt;SOLUTION: The cosmetic material comprises fine particle titanium oxide the surface of which is coated with hydrated silicic acid and/or a hydrated silicate, a higher alcohol, an oil-based component except the higher alcohol and a polysaccharide. The polysaccharide contains at least one species of fucose, glucose, glucuronic acid and rhamnose as a constituent monosaccharide. A polysaccharide containing fucose and/or rhamnose in its side chains is included in 0.01-1 wt.% based on the whole weight of the cosmetic material. The cosmetic material is in an emulsified state.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair-treating method which can enhance an effect for inhibiting the fading of hair dyed with an oxidation hair dye and can easily inhibit the deterioration in the flexibility of the hair, and to provide a post-treating agent kit.  &lt;P&gt;SOLUTION: At the first post-treating stage, the first post-treating agent is applied to hair wetted by washing away an oxidation hair dye. At a dry treating stage, the hair after the first post-treating stage is dried. At the second post-treating stage, the second post-treating agent is applied to the hair after the dry treating stage. The first and second post-treating agents contain a cationized chitosan and a surfactant. The surfactant is at least one selected from amphoteric surfactants having ≤18C alkyl groups, and cationic surfactants having ≤18C alkyl groups. The first post-treating agent contains the cationized chitosan in a larger mass rate than the cationized chitosan in the second post-treating agent. The post-treating agent kit is formed by containing the first and second post-treating agents.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To provide a hepatic function improving and hypotensive agent having high safety and the activity to decrease the GOT and GPT values in the serum effectively and the hypotensive activity, by using living or dead cells of microorganisms belonging to Streptococcus genus. CONSTITUTION:The objective agent for improving hepatic function and a hypotensor contains the living or dead cells of microorganisms belonging to Streptococcus genus (e.g. Streptococcus faecalis, faecium, bovis, etc.) as an active component. The microorganism is effective to lower the GOT and GPT values in serum as an agent for improving hepatic function and suppresses the blood pressure from the state of hypertension to the normal state as a hypotensor. It is useful as a remedy and preventive for myocardial infarction, cerebral apoplexy, arteriosclerosis, acute hepatitis, chronic hepatitis, hepatocirrhosis, etc. It is administered by oral administration, intravenous injection, etc., at a dose of 10&lt;7&gt;-10&lt;14&gt; cells per kg body weight.
PURPOSE: To obtain an allergic inflammation-inhibiting substance comprising the extract of an actinomycete, Streptomyces variabilis, low in toxicity and high in usefulness. CONSTITUTION: The allergic inflammation-inhibiting substance comprises the extract of the culture solution of an actinomycete, Streptomyces variabilis, or the cells with an organic solvent. The extract is prepared into an allergic inflammation-inhibiting preparation containing the extract in an amount of 10&lt;-8&gt; to 50wt.%. The allergic inflammation-inhibiting preparation is administered at a does not of 1pg to 500mg/kg as the allergic inflammation-inhibiting substance once to four times a day. The culture is performed in a culture medium having nutritive ingredients (e.g. a liquid medium containing glucose, malt extract and yeast extract and having a pH of 2-9) at 14-42 deg.C for 1-14 days. The extraction is performed by leaving or stirring the mixture of the culture solution with an organic solvent (e.g. ethyl acetate) for 3-120min.
FIELD: medicine, oncology. SUBSTANCE: 250 ml of peripheral venous autoblood is taken off and 150 ml of autoblood is incubated with antitumor chemopreparations. The remained 100 ml of blood are incubated with Intron-A taken in the dose 15 x 10 IU. Both mixtures taken in separated flasks are placed into thermostat at 37 C for 1 h. Then the blood mixture containing antitumor chemopreparations is infused by drop route for 25-30 min and blood mixture with Intron-A is infused for 2-3 h. Procedure is repeated on 8-th day. The total treatment course is 6. Method ensures to provide effective tumor cells killing in circulating blood and damaged foci, to decrease tumor size and lymph nodes, to decrease toxicity of administrated preparations, to stimulate immunoreactivity and total nonspecific immunological resistance of body. Invention can be used in treatment of patients with non-Hodgkin&#39;s lymphomas of II-IV stages of disease. EFFECT: enhanced effectiveness of treatment. 2 ex
PURPOSE:To obtain a lipid membranous structure for oral administration capable of efficiently conveying a held medicine to Peyer&#39;s patches in digestive tracts after administration and improving the absorbability of medicines which have been poor in absorbability in the oral administration. CONSTITUTION:A lipid membranous structure for oral administration is obtained by adding at least one selected from phosphatidylserine (preferably hydrogenated phosphatidylserine, dipalmitoylphosphatidylserine or distearoylphosphatidylserine), mannose derivatives and mannan derivatives as a membrane ingredient in an amount of &gt;=1%, preferably 5-50% molar fraction based on the total lipid membranous ingredient to a lipid membranous structure such as a liposome, an emulsion or a micelle. This lipid membranous structure has the above-mentioned effects. Furthermore, medicines capable of being held with the aforementioned lipid membranous structure vary with the kind of the lipid membranous structure, but are not especially limited in the case of, e.g. the liposome. Fat-soluble medicines and sparingly water-soluble medicines can be cited as the medicines capable of being held with the lipid membranous structure.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a magnetic apparatus having a multi-dimensional gradient for continuous on-line separation of components from a mixture of chemical substances such as a whole blood sample.  &lt;P&gt;SOLUTION: A microsphere internally including magnetic particles is agitated with a whole blood sample in a mixing chamber 12 and is connected to a blood ingredient (red blood cell) of the whole blood sample. The blood sample containing the blood ingredient connected with the microsphere is introduced into a first magnetic apparatus 20 having a separation chamber 22. The blood sample enters into the chamber 22 by passing through the entrance 23 thereof. The chamber 22 has a plurality of groove parts 25 and a plurality of magnets 27. The magnets 27 contact with each other. Additionally, the magnets form a certain magnetic field, collect the blood ingredient with the sticking microsphere in the groove parts 25 and the remaining blood (white cell, platelet, and plasma) is sent out from an exit 24 of the separation chamber 22 by passing through the groove parts 25.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a molded product of a foamable chlorinated isocyanuric acid, having excellent preservation stability, capable of reducing the abrasion of a mortar and a pounder used as a mold at pressure forming thereof, preventing the surfaces of the mortar and the pounder from being damaged, and enabling the use of a lubricant to be reduced.  &lt;P&gt;SOLUTION: The molded product of the foamable chlorinated isocyanuric acid is obtained by subjecting a formulated product of 100 pts. wt. chlorinated isocyanuric acid, 50-200 pts. wt. organic acid, 50-200 pts. wt. carbonic acid salt and 10-100 pts. wt. sodium sulfate having ≥45 and &lt;355 μm particle diameter to the pressure forming.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention relates to thienoimidazole-like derivatives and applications of the derivatives in inhibiting the activity of poly (ADP-ribose) polymerase. The derivatives are of a structure shown as a formula (I). According to the invention, the median inhibitory concentration of compounds with a structure shown as the formula (I) to poly (ADP-ribose) polymerase is generally about 10&lt;-7&gt; mol. L&lt;-1&gt;. The series of compounds can be applied to the prevention and treatment of tumors, ischemic diseases, diabetes and inflammatory diseases. The formula (I) is shown in the specification.
PCT No. PCT/DK82/00082 Sec. 371 Date Apr. 11, 1983 Sec. 102(e) Date Apr. 11, 1983 PCT Filed Sep. 14, 1982 PCT Pub. No. WO83/01074 PCT Pub. Date Mar. 31, 1983.Human insulin or B-30 esters thereof are prepared by reacting an insulin derivative of the formula &lt; IMAGE &gt; (I) wherein R is hydroxyl or an amino acid radical being different from threonine, and -A- and -B- represent the A- and B-chains with the same amino acid sequence as in human insulin, with a carboxyl protected and optionally hydroxyl protected L-threonine derivative in a concentration of from 2 to about 6 moles per liter in the presence of trypsin or a trypsin-like enzyme in a reaction medium containing water and optionally also an organic cosolvent at a pH value of from 5 to 9 and at a temperature below 50 DEG C., followed, if desired, by removal of any protecting groups present. Human insulin is prepared in an easy and simple way in high yield and in high purity.
Abstract A system and associated method are provided for fulfillment of medication requisitions corresponding to contained medication units. Requisition fulfillment logic may be included to provide decision data to a patient care provider for use in selecting one of a plurality of different fulfillment sites to fill a given medication requisition. A requisition router may route the medication requisition to a selected one of the plurality of fulfillment sites. The fulfillment sites may provide medication requisition metadata (e.g., data relating to the preparation and handling of medication units) to a medication requisition database in corresponding relation to the corresponding medication requisitions fulfilled by the fulfillment sites. The medication requisition metadata may be stored in the medication requisition database and accessed to facilitate enhanced management functionalities in relation to medication units dispensed by patient care providers. MEDICATION REQUISITION 100 MEDICATION MANAGEMENT NETWORK REQUISITION PATIENT CARE PROVIDER REQUISITION REQUISITION&#39; -- -- -- ---- --- + FULFILLMENT -0---- - -- - I LOGIC I60b 60a 40 REMOTE REQUISITION REMOTE FULFILLMENT ROUTER ---- FULFILLMENT \J- \ PHARMACY FULFILLMENT S7TE]
Provided herein are genetically modified microbes. In one embodiment, a genetically modified microbe includes an exogenous polynucleotide that includes a pheromone-responsive region. In one embodiment, the pheromone-responsive region is derived from a conjugative plasmid from a member of the genus  Enterococcus  spp. The pheromone-responsive region includes a pheromone-responsive promoter and an operably linked coding region encoding an antimicrobial peptide. In one embodiment, a genetically modified microbe includes an exogenous polynucleotide that includes a promoter and an operably linked coding sequence encoding an antimicrobial peptide, where expression of the coding region is controlled by a modulator polypeptide and is altered by a modulating agent, and where the coding region encodes an antimicrobial peptide. Also provided herein are methods of using the genetically modified microbes, including methods for inhibiting growth of an  Enterococcus  spp., a pathogenic  E. coli,  or a pathogenic  Salmonella  spp., for treating a subject, and for modifying a subject&#39;s gastrointestinal microflora.
PURPOSE:A whitening cosmetic having improved whiteness degree and improved stability, containing a p-dimethylaminobenzoic acid alkyl ester, ethanol and a surface active agent as active ingredients. CONSTITUTION:A whitening cosmetic containing (A) a p-dimethylaminobenzoic acid alkyl ester, (B) ethanol, and (C) a surface active agent as essential components. The alkyl group of the component A has preferably 3-10C, it may have a straight-chain or branched chain, and an amount of the component A blended is preferably 0.1-3wt%. An amount of the component B blended is preferably 1-30wt%, and an amount of the component C blended is preferably 0.1-5 times as much as the component A. The component C is required to have &gt;=10 HLB value,, and any of an anionic, a cationic, or an ampholytic surface active agent or their mixtures may be used. In producing the cosmetic, the component A and the component C is dissolved or dispersed in the component B, and dispersed into a water phase component, to give the aimed cosmetic.
A monitoring system for monitoring the physiological condition of a patient on a continuous basis, which includes a transmitter unit adapted to attach to a patient so as to be in contact with the skin of a patient, and a corresponding receiver unit. The transmitter unit includes a strap or belt adapted to attach to or around a body part of a patient. A plurality of sensors are mounted to the belt for monitoring a plurality of patient physiological parameters, including at least the patient&#39;s skin impedance, heart rate and aspects of the heart beat of the patient, the sensors adapted to each produce a signal related to the parameter being monitored. The sensors are connected to a microcontroller which processes the signals and a wireless transmitter to which the microcontroller is linked is adapted to transmit a radio signal related to the physiological conditions monitored by the sensors. A portable receiver unit is adapted to receive and process the signal received from the transmitter. The receiver unit includes display means for displaying data relating to the patient. The monitoring system generates output when the rate of change of patient physiological parameters indicates that hypoglycaemia is present or imminent. (61) Addition to 543267
FIELD: medicine, reanimatology, surgery, pathological physiology. SUBSTANCE: invention relates to the use of gelatin aqueous solutions or agar-agar for evaluation of manifestation of endotoxemia and degree of disease severity. Method is based on estimation of temperature shifting transient point &#34;sol-gel&#34; for gel-forming biological substances. The developed agent provides to carry out quantitative determination of degree and severity of manifestation of endotoxemia. EFFECT: enhanced effectiveness of agent, improved method of evaluation. 1 tbl
A dispenser is provided. The dispenser has a reservoir for storing a liquid or solid material. The dispenser may have a piezoelectric valve or pump located in an opening of the reservoir for regulating dispensing of the material. Alternatively, the dispenser may have a piezoelectric inchworm that directly or indirectly propels the material against or out of the opening. The opening may deposit the material directly or indirectly on the surface of an animal, or under the animal&#39;s skin. The dispenser also can be attached to the surface of the animal. Alternatively, the dispenser may be placed inside the animal.
A fluid dentifrice contains, in addition to glycerol and/or sorbitol as humectant and xanthan gum as binder, a precipitated silica polishing agent having characteristic particle size and specific surface properties to provide specific rheological properties.  A fluid dentifrice, containing polishing agents, humectants, binders and water, includes (a) 5-15 wt. % precipitated silica having an average particle size of 8-14  mu m, a BET specific surface of 40-75 m&lt;2&gt;/g and little thickening action, (b) 20-55 wt. % glycerol and/or sorbitol and (c) 0.3-1.0 wt. % xanthan gum as binder. The viscosity, measured at 20 deg C using a Type RTV Brookfield viscometer, is 10-100 Pa.s, the lower flow limit Fu being 10 Pa (20 deg C) and the upper flow limit being not more than twice the value of Fu.
318,269. Johnson, J. Y., (I. G. Farbenindustrie Akt.-Ges.). April 2, 1928. Vitamins.-Antirachitic preparations are obtained by treating ergosterol or substances containing it with corona discharges obtained by using continuous currents of high voltage or alternating currents of high voltage and frequency, or with electric corpuscular rays such as rapidlymoving electrons or ions or with R÷ntgen rays, while excluding oxygen, halogens, and the like. &#39;The ergosterol may be used in the solid, diluted, or vapour-like state. In the examples, (1) ergosterol is passed in suspension in a neutral gas such as nitrogen (or, if dissolved, in fog-like form) through an apparatus of the Cotterell-Moeller kind having spark electrodes and using a current at several hundred kilovolts; the progress of the treatment may be controlled by observing the ultraviolet absorption spectrum, and reduced pressure may be employed; (2) a solution of ergosterol in heptaine or the like is treated in an ozonizer using a high frequency alternating current having more than 1000 alternations per second and a tension of more than 1 kilovolt, a current of inert gas being passed through the solution; (3) ergosterol is subjected to the action of electrons or ions which are accelerated by an electrostatic field; the material may be spread in a thin layer on a dish and treated in a cathode tube, or, when using cathode rays of very high velocity, it may be effected outside the tube, the rays passing through an aluminium window; canal rays may also be used with an indifferent gas at low pressure; (4) ergosterol is treated in solid form with X-rays, a substance such as barium platinocyanide or zinc sulphide being added if desired to effect a secondary emission of ultraviolet rays. The electric treatment above described may be combined with a treatment with ultraviolet rays. Specifications 292,926; and 293,255, [Class 1 (i), Chemical processes &amp;c.], are referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To establish a technique for establishing an immortalized mesangial cell derived from a human, sub-culturable over a long period and holding or inducing characters of a differentiated type plasmocyte.  &lt;P&gt;SOLUTION: An hTERT (human telomerase reverse transcription enzyme) gene constitutively expressing with an SV40T antigenic gene is transferred. Thereby, the immortalized mesangial cell derived from the human and stably maintaining the proliferation can be established. The immortalized mesangial cell can be cultured under non-permissive conditions for expressing the SV40 antigen to thereby provide the differentiated type human mesangial cell. The immortalized human mesangial cell and the differentiated type human mesangial cell are useful for screening substances modulating functions of the human mesangial cell.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention provides a vaccine candidate strain XZ05 delta meq with marek&#39;s disease virus meq gene editing deletion, construction and application. The XZ05 delta meq vaccine strain of the invention has the preservation number of: CGMCC No.45865. The parent strain of the XZ05 delta meq vaccine strain is MDV ultra-strong Chinese variant strain HNXZ. After in vitro passaging of the parental strain HNXZ, 925bp sized fragments were deleted on each of the two meq alleles of the viral genome using CRISPR/Cas9 gene editing techniques. The complete deletion of both meq alleles by XZ05. Delta. Meq was confirmed by PCR identification, sequencing of gene clones, RT-qPCR analysis, IFA identification. Animal immune toxicity attack protection evaluation experiments show that XZ05 delta meq has good immune protection, and the immune protection index of the currently popular extra-strong MDV Chinese variant HNSQ01 reaches 82.4%. Therefore, the XZ05 delta meq strain constructed by the invention not only can be used as a candidate strain of the latest MD gene deletion vaccine, but also can be used for developing and utilizing a subsequent MD novel genetic engineering vaccine.
PURPOSE: To form a spheroidal microcapsule whose diameter is less than 150 μm by mixing respectively specific amount of a medicament, a film-forming polymer and a plasticizing agent to form a water-soluble mixture, and spray- drying the mixture at a specific condition through a spray dryer. CONSTITUTION: A homogeneous water-soluble mixture, wherein 0.25 to 50 wt.% of a medicament with respect to the wt. of the mixture, 5 to 40 wt.% of a film-forming polymer with respect to the wt. of mixture and 5 to 30% of a plasticizing agent with respect to the wt. of the film-forming polymer are present, is prepared. After this water-soluble mixture is introduced into a pray drier under conditions so controlled as to allow the spheroidal microcapsules to be formed, the mixture is spray-dried, thereby the spheroidal microcapsules with &lt;=150 μm diameters are obtained. Examples of suitable medicaments are dextrometorphan, pseudoephedorine or the like.